Evolution of Solutions
Over millions of years, nature evolves mechanisms to treat and prevent disease.
Evolution has already honed molecules and mechanisms that overcome life-threatening conditions. This occurred over hundreds of millions of years of evolutionary time.
Elephants are resistant to cancer because their genomes contain dozens of copies of a tumor-suppressive gene (for reference, humans only have two copies).
An ancient Chinese tree holds innate, anti-cancer fighting properties that have been shown to effectively treat cancer.
Honeybee venom drills holes into red blood cells and upregulates part of the immune system that helps to attack cancer.
Hibernating bears avoid blood clots while not moving for months at a time by downregulating total body inflammation.
Bowhead whales live for over 200 years with natural ability to avoid cancer and keep their DNA-free from mutations.
At Peel, we translate these awe-inspiring discoveries into medicines for patients with life-threatening diseases. By applying our expertise in evolutionary biology with a deep understanding of how medicines function in the human body, we identify new targets and introduce evolutionary medicines as safe and efficacious treatments for people with devastating cancers and immune diseases.
At Peel Therapeutics, our technologies and expertise enable our company to deliver on the therapeutic potential of evolutionary outliers that circumvent disease.
Our team seeks the distinct molecules and genetic pathways in nature based on evolutionary discoveries that exceed what we’ve deemed biologically possible. We use our Darwin.AI™ proprietary discovery engine to identify new drug targets to develop. We are selective in the programs we move through our pipeline and our process includes assessing a potential asset’s impact on human physiology, efficacy and safety.
Our multidisciplinary R&D team includes experts in A.I., evolutionary biology, immunology, cancer research, protein and chemical engineering, drug delivery, clinical trials and medical practice to create a deep understanding that enables us to develop evolutionary medicines to have a lasting impact for patients.
One of our biggest advantages is our Peel Israel site focused on early discovery and lead candidate development. The scientists of Peel Israel have vast experience in molecular biology, protein engineering, analytical biochemistry, immunology, and drug delivery. The labs are equipped with state-of-the-art instruments and additional high-end equipment is available at the adjacent Technion Israel-Institute of Technology Cores. Peel Israel’s nimble drug development processes redesign nature’s offerings into medicines by improving formulation, stability, and efficacy. Our Peel Israel site acts as the springboard for Peel’s drug pipeline and IND-enabling studies.